Onera Healtha startup that provides diagnostic and sleep monitoring technology to help clinicians conduct studies, has lifted up 30 million euros ($32 million) in a Series C funding round.
Poor sleep is thought to only affect the US economy amounting to 400 billion dollarsdue to factors such as absence and sleep presentable.
While there are already countless sleep trackers on the market, Onera is best sold as a clinical-grade solution, having secured regulatory permission from similar the Food and Drug Administration (FDA) in the U.S. The company provides end-to-end “polysomnography-as-a-service,” allowing healthcare professionals to conduct a sleep study directly in the patient’s home — or in a lab, if required.
It works like this: The clinician orders a polysomnography study (PSG) through Onera, which sends the necessary sensors directly to the patient, who then attaches the sensors as instructed – it includes four wireless machines that are attached to the forehead, in the upper part of the chest, in the abdomen. area and lower leg.
The patient returns all the material back to Onera, which processes the data in its own cloud and produces a report for review by the clinician.
Founded from the Netherlands in 2017, Onera has now raised €55 million since inception, with the latest Series C round led by EQT Life Sciences and Gimv, with participation from Innovation Industries, Invest-NL, Imec.xpand, BOM and 15th Rock.
With a fresh €30m in the bank, the company said it plans to fast-track regulatory clearance for a second-generation PSG system in both the US and Europe, where it currently serves the Benelux (Belgium, Netherlands and Luxembourg) and DACH (Germany, Austria Switzerland) regions.
“We will continue to invest aggressively in R&D, customer success and geographic expansion to help the medical field provide the answers needed for millions of people affected by sleep disorders,” said Onera founder and CEO Ruben de Francisco .
